Changes of serum growth factors (IGF-I & IGFBP-2) and prediction of response to chemotherapy in patients with acute myeloid leukemia.
El-Naggar
Amel A
AA
Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Mahmoud
Bothaina F
BF
Abou Shamaa
Lobna A
LA
Salama
Mona A
MA
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
D018971:Insulin-Like Growth Factor Binding Protein 2; D003561:Cytarabine; D007334:Insulin-Like Growth Factor I; D004317:Doxorubicin